• 06 Aug 20

CEO updates on completing Phase 2b trial and future plans

CEO updates on completing Phase 2b trial and future plans

Destiny Pharma Plc | DTTYF | 0 0 0%

    • 234 views

 

Neil Clark is interviewed for 18 mins about  the ongoing XF-73 trial set to close this year, Covid highlighting risk of antibiotic resistant infections, and commercial plans.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

Destiny Pharma (DEST) - Hot Stocks on Vox Markets

Companies: Destiny Pharma Plc

Destiny Pharma presents at the Proactive One2One live investment forum

Companies: Destiny Pharma Plc

Destiny Pharma (DEST) - Hot Stocks on Vox Markets

Companies: Destiny Pharma Plc

Destiny Pharma: 'Opportunities for quality assets that deliver solutions for infection prevention'

Companies: Destiny Pharma Plc

Destiny Pharma (DEST) - Hot Stocks on Vox Markets

Companies: Destiny Pharma Plc

Destiny Pharma - Neil Clark, CEO (AIM:DEST) One2One Virtual Forum 10th December 2021

Companies: Destiny Pharma Plc

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top